SI2503338T1 - CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij - Google Patents

CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij

Info

Publication number
SI2503338T1
SI2503338T1 SI200831377T SI200831377T SI2503338T1 SI 2503338 T1 SI2503338 T1 SI 2503338T1 SI 200831377 T SI200831377 T SI 200831377T SI 200831377 T SI200831377 T SI 200831377T SI 2503338 T1 SI2503338 T1 SI 2503338T1
Authority
SI
Slovenia
Prior art keywords
biomarker
therapies
assessing
efficacy
diseases
Prior art date
Application number
SI200831377T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of SI2503338T1 publication Critical patent/SI2503338T1/sl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SI200831377T 2007-10-24 2008-10-15 CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij SI2503338T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
EP12002502.8A EP2503338B1 (en) 2007-10-24 2008-10-15 CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
SI2503338T1 true SI2503338T1 (sl) 2015-06-30

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200830723T SI2201376T1 (sl) 2007-10-24 2008-10-15 Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij
SI200831377T SI2503338T1 (sl) 2007-10-24 2008-10-15 CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200830723T SI2201376T1 (sl) 2007-10-24 2008-10-15 Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij

Country Status (14)

Country Link
US (1) US20100209942A1 (sl)
EP (2) EP2503338B1 (sl)
JP (2) JP4982610B2 (sl)
KR (2) KR20100059902A (sl)
CA (1) CA2702635A1 (sl)
CY (2) CY1113403T1 (sl)
DK (2) DK2201376T3 (sl)
ES (2) ES2389751T3 (sl)
FI (1) FI20070795A0 (sl)
HR (2) HRP20120743T1 (sl)
PL (2) PL2201376T3 (sl)
PT (2) PT2503338E (sl)
SI (2) SI2201376T1 (sl)
WO (1) WO2009053523A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200091961A (ko) 2008-01-18 2020-07-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
MX361944B (es) 2010-07-23 2018-12-19 President And Fellows Of Harvard College Star Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
EP2596353A4 (en) 2010-07-23 2014-01-15 Harvard College METHOD FOR DETECTING PRENATAL OR PREGNANT DISEASES OR SUFFERING
AU2011281012A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
KR20130041962A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법
EA201590024A1 (ru) 2012-06-15 2015-05-29 Гарри Стилли Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
MX2014015425A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones.
HUE038959T2 (hu) * 2013-02-14 2018-12-28 Faron Pharmaceuticals Oy Eljárás akut légúti distressz szindrómával (ARDS) összefüggõ biomarkerek kimutatására, illetve eljárás az ARDS betegben történõ kifejlõdésének és kezelésének monitorozására
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
EP2965086A4 (en) 2013-03-09 2017-02-08 Harry Stylli Methods of detecting prostate cancer
EP4075139B1 (en) 2014-09-11 2024-05-22 Immunis.AI, Inc. Methods of detecting prostate cancer
SI3221346T1 (sl) 2014-11-21 2020-11-30 Bristol-Myers Squibb Company Protitelesa vsebujoča modificirana težko konstantna območja
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727445B2 (en) * 1995-08-18 2000-12-14 Donald W Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
WO1997013875A1 (en) * 1995-10-13 1997-04-17 Imperial College Of Science, Technology & Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
JP2005503765A (ja) * 2001-03-27 2005-02-10 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
EP1608400B1 (en) * 2003-03-28 2010-06-23 Faron Pharmaceuticals OY Elevation of adenosine level by cytokine-induced expression of cd73
WO2005000860A2 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
US20100048501A1 (en) * 2006-03-21 2010-02-25 Heinrich-Heine-Universitat Dusseldorf Phosphorylated A2A Receptor Agonists
WO2008008284A2 (en) * 2006-07-14 2008-01-17 The Regents Of The University Of California Cancer biomarkers and methods of use threof

Also Published As

Publication number Publication date
KR20160029869A (ko) 2016-03-15
JP2011501176A (ja) 2011-01-06
PT2201376E (pt) 2012-08-20
EP2201376A4 (en) 2011-03-23
PL2503338T3 (pl) 2015-06-30
EP2503338A3 (en) 2013-03-13
CY1116089T1 (el) 2017-02-08
EP2503338A2 (en) 2012-09-26
CA2702635A1 (en) 2009-04-30
JP2012159514A (ja) 2012-08-23
HRP20150181T1 (hr) 2015-06-19
EP2201376B1 (en) 2012-08-08
JP5619810B2 (ja) 2014-11-05
WO2009053523A1 (en) 2009-04-30
DK2201376T3 (da) 2012-10-15
ES2389751T3 (es) 2012-10-31
SI2201376T1 (sl) 2012-09-28
US20100209942A1 (en) 2010-08-19
PT2503338E (pt) 2015-03-05
EP2201376A1 (en) 2010-06-30
EP2503338B1 (en) 2014-12-24
CY1113403T1 (el) 2016-06-22
HRP20120743T1 (hr) 2012-10-31
JP4982610B2 (ja) 2012-07-25
DK2503338T3 (en) 2015-03-09
PL2201376T3 (pl) 2013-01-31
KR20100059902A (ko) 2010-06-04
ES2532361T3 (es) 2015-03-26
FI20070795A0 (fi) 2007-10-24

Similar Documents

Publication Publication Date Title
HRP20150181T1 (hr) Cd73 kao biomarker za praä†enje razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
HK1256407A1 (zh) 未來心臟事件生物標記
ZA201108907B (en) New biomarkers for assessing kidney diseases
GB0724735D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
GB0701626D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
IL219210A0 (en) Biomarkers and methods for measuring and monitoring inflammatory disease activity
GB0624858D0 (en) Battery Monitoring
EP2024512A4 (en) METHODS FOR THE DIAGNOSIS OF ABNORMAL F CHARACTERS
EP2158326A4 (en) BIOMARKERS FOR THE DIAGNOSIS OF AUTOIMMUNE DISEASES
GB0608829D0 (en) In-situ measurement of physical parameters
EP2079484A4 (en) MONITORING OF CANCER STEM CELLS
GB2450351B (en) Monitoring an Immunoassay
IL206631A0 (en) Biomarkers for the prediction of renal injury
IL217725A0 (en) Means and methods for diagnosing thyroid disorders
TWI351185B (en) Methods for interference measurement and prediction
EP2222689A4 (en) THERAPEUTIC AND DIAGNOSTIC COMPOUNDS
GB0722068D0 (en) Predictive test
GB0720433D0 (en) Usage monitoring
EP2209565A4 (en) MONITORING INDEPENDENT VIBRATORS
AU2009900444A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0606920D0 (en) Biomarker for schizophrenic disorders
PL382585A1 (pl) Sposób realizowania transakcji handlowych
PL381454A1 (pl) Sposób diagnozowania stanu technicznego obiektów mostowych
AU2008902580A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0720545D0 (en) Diagnosing physchotic disorders